Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 56, 2022 - Issue 1
Journal homepage
1,260
Views
0
CrossRef citations to date
0
Altmetric
Articles

Inflammatory response markers and survival prediction in patients with renal cell carcinoma

Alexander Mountziasa Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, SwedenView further author information
,
Johan Hultdinb Department of Medical Biosciences, Clinical Chemistry, Umeå University, Umeå, SwedenORCID Iconhttps://orcid.org/0000-0002-9599-0961View further author information
ORCID Icon,
Jan Hlodana Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, SwedenView further author information
,
Britt-Inger Kröger Dahlina Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, SwedenView further author information
,
Mattias Johanssonc International Agency for Research on Cancer (IARC), Lyon, FranceView further author information
&
Börje Ljungberga Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4121-3753View further author information
ORCID Icon
Pages 47-52 | Received 24 Jun 2021, Accepted 16 Sep 2021, Published online: 29 Sep 2021

References

  • Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387.
  • Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953.
  • Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810.
  • Aarstad HH, Guðbrandsdottir G, Hjelle KM, et al. The biological context of C-reactive protein as a prognostic marker in renal cell carcinoma: studies on the acute phase cytokine profile. Cancers (Basel). 2020;12(7):1961.
  • Steffens S, Köhler A, Rudolph R, et al. Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer. 2012;12:399.
  • Chen Z, Shao Y, Wang K, et al. Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and Meta-analysis. Onco Targets Ther. 2016;9:6701–6710.
  • McMillan DC, Elahi MM, Sattar N, et al. Measurement of the systemic inflammatory response predicts cancer‐specific and non‐cancer survival in patients with cancer. Nutr Cancer. 2001;41(1–2):64–69.
  • Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754.
  • Komai Y, Saito K, Sakai K, et al. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 2007;99(1):77–80.
  • Lamb GW, Aitchison M, Ramsey S, et al. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. Br J Cancer. 2012;106(2):279–283.
  • Hu X, Wang Y, Yang WX, et al. Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and Meta-analysis. CMAR. 2019;11:6163–6173.
  • Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183(2):131–133.
  • Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–663.
  • Brierley JD, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. 8th ed. Oxford: Wiley-Blackwell; 2017.
  • Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–655.
  • Hu Q, Gou Y, Sun C, et al. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and Meta-analysis. Urol Oncol. 2014;32(1):50.e1-8–50.e8.
  • Fukuda H, Takagi T, Kondo T, et al. Predictive value of inflammation-based prognostic scores in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy. Oncotarget. 2018;9(18):14296–14305.
  • Fan H, Shao ZY, Xiao YY, et al. Comparison of the glasgow prognostic score (GPS) and the modified glasgow prognostic score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer. J Cancer Res Clin Oncol. 2016;142(6):1285–1297.
  • Ueda K, Ogasawara N, Yonekura S, et al. The prognostic value of systemic inflammatory markers in advanced renal cell carcinoma patients treated with molecular targeted therapies. Anticancer Res. 2020;40(3):1739–1745.
  • Suzuki K, Terakawa T, Furukawa J, et al. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab. Int J Clin Oncol. 2020;25(1):135–144.
  • Fukuda S, Saito K, Yasuda Y, et al. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. J Immunother Cancer. 2021;9(2):e001564.
  • Lindskog M, Wahlgren T, Sandin R, et al. Overall survival in swedish patients with renal cell carcinoma treated in the period 2002 to 2012: update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations. Urol Oncol. 2017;35(9):541.e15–541.e22.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.